* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
This filing lists securities holdings reported on the form 13F filed on 14 Feb 2023 pursuant to a request for confidential treatment and for which confidential treatment expired on 05 Jan 2024.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Thomas Anderman
President & Chief Investment Officer
New York, New York
11 Jan 2024
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.